Trans-4--n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
AssigneeRichter Gedeon Nyrt.
InventorsJános György Pitter, Balázs Szatmári, Marc Debelle, György József Németh, István Laszlovszky
Life of this patent
Estimating the term…
Abstract
The present invention relates to trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine (cariprazine) and pharmaceutically acceptable salts and hydrates and solvates and polymorphs thereof for use in the treatment of primary negative symptoms of schizophrenia and/or predominantly negative symptoms of schizophrenia.
Claims4
A method of treating one or more primary negative symptoms of schizophrenia, the method comprising administering to a patient in need thereof a therapeutically effective amount of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
A method of treating predominantly negative symptoms of schizophrenia, the method comprising administering to a patient in need thereof a therapeutically effective amount of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
Dependencies are inferred from the claim text.